Fibroblast growth factor receptor 1 signaling in adult cardiomyocytes increases contractility and results in a hypertrophic cardiomyopathy

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Cilvik, Sarah N ^a   Wang, Joy I ^a   Lavine, Kory J ^a   Uchida, Keita ^a   Castro, Angela ^a   Gierasch, Carolyn M ^a   Weinheimer, Carla J ^a   House, Stacey L ^a   Kovacs, Attila ^a   Nichols, Colin G ^a   Ornitz, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2; TROPONIN I; UNCLASSIFIED DRUG; FGFR1 PROTEIN, MOUSE;

ACTIN MYOSIN INTERACTION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; FEMALE; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE RELAXATION; HISTOLOGY; HYPERTROPHIC CARDIOMYOPATHY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYSTOLE; ANIMAL; CARDIOMEGALY; DISEASE MODEL; ECHOCARDIOGRAPHY; ECHOGRAPHY; GENETICS; HEART CONTRACTION; HEART VENTRICLE REMODELING; HEMODYNAMICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; HEMODYNAMICS; MICE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84892425475     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082979     Document Type: Article

References (53)

1. Barry SP, Davidson SM, Townsend PA (2008) Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 40: 2023-2039. doi: 10.1016/j.biocel.2008. 02.020. PubMed: 18407781.
2. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7: 589-600. doi: 10.1038/nrm1983. PubMed: 16936699.
3. Ho CY (2010) Hypertrophic cardiomyopathy. Heart Fail Clin 6: 141-159. doi:10.1016/j.hfc.2009.12.001. PubMed: 20347784.
4. Tsoutsman T, Lam L, Semsarian C (2006) Genes, calcium and modifying factors in hypertrophic cardiomyopathy. Clin Exp Pharmacol Physiol 33: 139-145. doi:10.1111/j.1440-1681.2006.04340.x. PubMed: 16445713.
5. Izumo S, Nadal-Ginard B, Mahdavi V (1988) Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A 85: 339-343. doi:10.1073/pnas.85.2.339. PubMed: 2963328.
6. Izumo S, Lompré AM, Matsuoka R, Koren G, Schwartz K et al. (1987) Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest 79: 970-977. doi: 10.1172/JCI112908. PubMed: 2950137.
7. Lompré AM, Mercadier JJ, Schwartz K (1991) Changes in gene expression during cardiac growth. Int Rev Cytol 124: 137-186. PubMed: 1825818.
8. Schoenfeld JR, Vasser M, Jhurani P, Ng P, Hunter JJ et al. (1998) Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. J Mol Cell Cardiol 30: 2269-2280. doi: 10.1006/jmcc.1998.0787. PubMed: 9925364.
9. Schwartz K, de la Bastie D, Bouveret P, Oliviéro P, Alonso S et al. (1986) Alpha-skeletal muscle actin mRNA's accumulate in hypertrophied adult rat hearts. Circ Res 59: 551-555. doi: 10.1161/01.RES.59.5.551. PubMed: 2948733.
10. Kaye D, Pimental D, Prasad S, Mäki T, Berger HJ et al. (1996) Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. J Clin Invest 97: 281-291. doi:10.1172/JCI118414. PubMed: 8567946.
11. Schultz JE, Witt SA, Nieman ML, Reiser PJ, Engle SJ et al. (1999) Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest 104: 709-719. doi:10.1172/JCI7315. PubMed: 10491406.
12. Scheinowitz M, Abramov D, Kotlyar A, Savion N, Eldar M (1998) Continuous administration of insulin-like growth factor-I and basic fibroblast growth factor does not affect left ventricular geometry after acute myocardial infarction in rats. Int J Cardiol 63: 217-221. doi: 10.1016/S0167-5273(97)00322- 7. PubMed: 9578347.
13. Virag JA, Rolle ML, Reece J, Hardouin S, Feigl EO et al. (2007) Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol 171: 1431-1440. doi:10.2353/ajpath.2007.070003. PubMed: 17872976.
14. House SL, House BE, Glascock B, Kimball T, Nusayr E et al. (2010) Fibroblast Growth Factor 2 Mediates Isoproterenol-induced Cardiac Hypertrophy through Activation of the Extracellular Regulated Kinase. Mol Cell. Pharmacol 2: 143-154.
15. Pellieux C, Foletti A, Peduto G, Aubert JF, Nussberger J et al. (2001) Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 108: 1843-1851. doi: 10.1172/JCI200113627. PubMed: 11748268.
16. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A et al. (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest, 121: 4393-408. PubMed: 21985788.
17. Korf-Klingebiel M, Kempf T, Schlüter KD, Willenbockel C, Brod T et al. (2011) Conditional transgenic expression of fibroblast growth factor 9 in the adult mouse heart reduces heart failure mortality after myocardial infarction. Circulation 123: 504-514. doi:10.1161/CIRCULATIONAHA.110.989665. PubMed: 21262993.
18. Yang G, Meguro T, Hong C, Asai K, Takagi G et al. (2001) Cyclosporine reduces left ventricular mass with chronic aortic banding in mice, which could be due to apoptosis and fibrosis. J Mol Cell Cardiol 33: 1505-1514. doi:10.1006/jmcc.2001.1413. PubMed: 11448138.
19. Teranishi F, Takahashi N, Gao N, Akamo Y, Takeyama H et al. (2009) Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo. Cancer Sci 100: 770-777. doi:10.1111/j.1349-7006.2009.01084.x. PubMed: 19469020.
20. Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP et al. (2002) The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 109: 1013-1020. doi: 10.1172/JCI0214677. PubMed: 11956238.
21. Li H, He C, Feng J, Zhang Y, Tang Q et al. (2010) Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci U S A 107: 13818-13823. doi:10.1073/pnas.1008397107. PubMed: 20643937.
22. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA et al. (1999) Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 84: 735-740. doi:10.1161/01.RES.84.6.735. PubMed: 10189362.
23. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L et al. (2010) Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Invest 120: 3520-3529. doi:10.1172/JCI42028. PubMed: 20811150.
24. Zhang HX, Akrouh A, Kurata HT, Remedi MS, Lawton JS et al. (2011) HMR 1098 is not an SUR isotype specific inhibitor of heterologous or sarcolemmal K ATP channels. J Mol Cell Cardiol 50: 552-560. doi: 10.1016/j.yjmcc.2010.12.011. PubMed: 21185839.
25. Valencik ML, McDonald JA (2001) Codon optimization markedly improves doxycycline regulated gene expression in the mouse heart. Transgenic Res 10: 269-275. doi:10.1023/A:1016601928465. PubMed: 11437283.
26. Naski MC, Wang Q, Xu J, Ornitz DM (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13: 233-237. doi:10.1038/ng0696-233. PubMed: 8640234.
27. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H (2007) Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 12: 331-343. doi:10.1007/s10741-007-9034-1. PubMed: 17516164.
28. van den Bosch BJ, Lindsey PJ, van den Burg CM, van der Vlies SA, Lips DJ et al. (2006) Early and transient gene expression changes in pressure overload-induced cardiac hypertrophy in mice. Genomics 88: 480-488. doi:10.1016/j.ygeno.2006.04.012. PubMed: 16781840.
29. Böttcher RT, Niehrs C (2005) Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 26: 63-77. doi:10.1210/er.2003- 0040. PubMed: 15689573.
30. Zhang Z, Verheyden JM, Hassell JA, Sun X (2009) FGF-regulated Etv genes are essential for repressing Shh expression in mouse limb buds. Dev Cell 16: 607-613. doi:10.1016/j.devcel.2009.02.008. PubMed: 19386269.
31. Burkhoff D, Mirsky I, Suga H (2005) Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 289: H501-H512. doi:10.1152/ajpheart.00138.2005. PubMed: 16014610.
32. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129. doi:10.1038/nrc2780. PubMed: 20094046.
33. Saucerman JJ, McCulloch AD (2006) Cardiac beta-adrenergic signaling: from subcellular microdomains to heart failure. Ann N Y Acad Sci 1080: 348-361. doi:10.1196/annals.1380.026. PubMed: 17132794.
34. Backx PH, Gao WD, Azan-Backx MD, Marban E (1994) Mechanism of force inhibition by 2,3-butanedione monoxime in rat cardiac muscle: roles of [Ca2+]i and cross-bridge kinetics. J Physiol 476: 487-500. PubMed: 8057256.
35. Flagg TP, Cazorla O, Remedi MS, Haim TE, Tones MA et al. (2009) Ca2+-independent alterations in diastolic sarcomere length and relaxation kinetics in a mouse model of lipotoxic diabetic cardiomyopathy. Circ Res 104: 95-103. PubMed: 19023131.
36. Koitabashi N, Kass DA (2012) Reverse remodeling in heart failure - mechanisms and therapeutic opportunities. Nat Rev Cardiol 9: 147-157. PubMed: 22143079.
37. Fifer MA, Vlahakes GJ (2008) Management of symptoms in hypertrophic cardiomyopathy. Circulation 117: 429-439. doi:10.1161/CIRCULATIONAHA.107.694158. PubMed: 18212300.
38. Marian AJ (2009) Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J 36: 194-204. PubMed: 19568388.
39. Tidyman WE, Rauen KA (2008) Noonan, Costello and cardio-faciocutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med 10: e37. doi:10.1017/S1462399408000902. PubMed: 19063751.
40. Zheng M, Dilly K, Dos Santos Cruz J, Li M, Gu Y et al. (2004) Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am J Physiol Heart Circ Physiol 286: H424- H433. PubMed: 12969887.
41. Layland J, Solaro RJ, Shah AM (2005) Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 66: 12-21. doi: 10.1016/j.cardiores.2004.12.022. PubMed: 15769444.
42. Winegrad S (1984) Regulation of cardiac contractile proteins. Correlations between physiology and biochemistry. Circ Res 55: 565-574. doi:10.1161/01.RES.55.5.565. PubMed: 6091939.
43. Deshmukh PA, Blunt BC, Hofmann PA (2007) Acute modulation of PP2a and troponin I phosphorylation in ventricular myocytes: studies with a novel PP2a peptide inhibitor. Am J Physiol Heart Circ Physiol 292: H792-H799. PubMed: 17012362.
44. Jideama NM, Crawford BH, Hussain AK, Raynor RL (2006) Dephosphorylation specificities of protein phosphatase for cardiac troponin I, troponin T, and sites within troponin T. Int J Biol Sci 2: 1-9. PubMed: 16585947.
45. Wijnker PJ, Boknik P, Gergs U, Müller FU, Neumann J et al. (2011) Protein phosphatase 2A affects myofilament contractility in non-failing but not in failing human myocardium. J Muscle Res Cell Motil 32: 221-233. doi:10.1007/s10974-011-9261-x. PubMed: 21959857.
46. Yang F, Aiello DL, Pyle WG (2008) Cardiac myofilament regulation by protein phosphatase type 1alpha and CapZ. Biochem Cell Biol 86: 70-78. doi:10.1139/O07-150. PubMed: 18364747.
47. Dougherty MK, Müller J, Ritt DA, Zhou M, Zhou XZ et al. (2005) Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17: 215-224. doi:10.1016/j.molcel.2004.11.055. PubMed: 15664191.
48. Kolupaeva V, Laplantine E, Basilico C (2008) PP2A-mediated dephosphorylation of p107 plays a critical role in chondrocyte cell cycle arrest by FGF. PLOS ONE 3: e3447. doi:10.1371/journal.pone.0003447. PubMed: 18927618.
49. Lao DH, Yusoff P, Chandramouli S, Philp RJ, Fong CW et al. (2007) Direct binding of PP2A to Sprouty2 and phosphorylation changes are a prerequisite for ERK inhibition downstream of fibroblast growth factor receptor stimulation. J Biol Chem 282: 9117-9126. doi:10.1074/jbc.M607563200. PubMed: 17255109.
50. Robinson P, Griffiths PJ, Watkins H, Redwood CS (2007) Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ Res 101: 1266-1273. doi:10.1161/CIRCRESAHA.107.156380. PubMed: 17932326.
51. Wang Y, Pinto JR, Solis RS, Dweck D, Liang J et al. (2012) Generation and functional characterization of knock-in mice harboring the cardiac troponin I-R21C mutation associated with hypertrophic cardiomyopathy. J Biol Chem 287: 2156-2167. doi:10.1074/jbc.M111.294306. PubMed: 22086914.
52. Kranias EG, Hajjar RJ (2012) Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 110: 1646-1660. doi: 10.1161/CIRCRESAHA.111.259754. PubMed: 22679139.
53. Ather S, Respress JL, Li N, Wehrens XH (2013) Alterations in ryanodine receptors and related proteins in heart failure. Biochim Biophys Acta (. (2013)) PubMed: 23770282.